Novartis Doan's back pain relief superiority claims not supported, FTC judge concludes.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS DOAN'S BACK PAIN RELIEF SUPERIORITY CLAIMS NOT SUPPORTED, FTC Administrative Law Judge Lewis Parker said in a March 9 decision and order upholding charges made by the Federal Trade Commission. Novartis is prohibited from claiming Doan's "is more effective than other over-the-counter analgesic drugs for relieving back pain or any other particular kind of pain, unless, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation," the order states.
You may also be interested in...
Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.
Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.
Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.